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ABSTRACT To replicate efficiently, viruses must create favorable cell conditions and
overcome cell antiviral responses. We previously reported that the reovirus protein
2 from strain T1L, but not strain T3D, represses one antiviral response: alpha/beta
interferon signaling. We report here that T1L, but not T3D, 2 localizes to nuclear
speckles, where it forms a complex with the mRNA splicing factor SRSF2 and alters its
subnuclear localization. Reovirus replicates in cytoplasmic viral factories, and there is no
evidence that reovirus genomic or messenger RNAs are spliced, suggesting that T1L 2
might target splicing of cell RNAs. Indeed, RNA sequencing revealed that reovirus T1L,
but not T3D, infection alters the splicing of transcripts for host genes involved in mRNA
posttranscriptional modifications. Moreover, depletion of SRSF2 enhanced reovirus
replication and cytopathic effect, suggesting that T1L 2 modulation of splicing
benefits the virus. This provides the first report of viral antagonism of the splicing
factor SRSF2 and identifies the viral protein that determines strain-specific differ-
ences in cell RNA splicing.
IMPORTANCE Efficient viral replication requires that the virus create favorable cell
conditions. Many viruses accomplish this by repressing specific antiviral responses.
We demonstrate here that some mammalian reoviruses, RNA viruses that replicate
strictly in the cytoplasm, express a protein variant that localizes to nuclear speckles,
where it targets a cell mRNA splicing factor. Infection with a reovirus strain that tar-
gets this splicing factor alters splicing of cell mRNAs involved in the maturation of
many other cell mRNAs. Depletion of this cell splicing factor enhances reovirus repli-
cation and cytopathic effect. Our results provide the first evidence of viral antago-
nism of this splicing factor and suggest that downstream consequences to the cell
are global and benefit the virus.
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Viruses are obligatory intracellular pathogens that require a hospitable cell environ-ment for their replication. However, viral infection induces cell innate responses
that are antiviral. Accordingly, viruses have evolved numerous strategies to evade these
responses. For example, viral infection of virtually any cell type induces a protective
type I interferon (IFN-/) response, and many viruses use at least one mechanism to
suppress this antiviral system (1, 2). Viral proteins that inhibit cell antiviral responses
have been identified for most viruses, as have the cell proteins they target (1, 3). Not
surprisingly, the most commonly identified targets are cell proteins involved in the
IFN-/ response (1, 2).
Mammalian reoviruses are double-stranded RNA nonenveloped viruses that repli-
cate in membrane-associated cytoplasmic viral factories (VFs) (4, 5). Reovirus strain type
1 Lang (T1L) represses IFN- signaling, while type 3 Dearing (T3D) does not (6), and this
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difference is determined by the reovirus 2 protein (6, 7) encoded by the M1 gene. 2
is a minor capsid protein but is expressed abundantly in infected cells and has RNA
binding (8) and NTPase activities (9, 10). It also determines virus strain-specific differ-
ences in the morphology of VFs through its capacity to bind and stabilize microtubules
(10, 11). Strain-specific differences in repression of IFN- signaling and stabilization of
microtubules are determined by a polymorphism in amino acid 208 of the 2 protein
(6, 7, 11). This may reflect the impact of amino acid 208 on 2 stability (12) or on 2
function. During infection, 2 localizes predominantly to VFs (10–13) but can also be
visualized diffusely in the cytoplasm and nucleus (10, 11, 14). However, the role of 2
in the nucleus remains to be elucidated.
Here, we show that 2 from T1L and reovirus recombinants that encode the T1L 2
amino acid polymorphism form a complex with the pre-mRNA splicing factor SRSF2
(previously known as SC35 [15]) in nuclear speckles. Moreover, T1L but not T3D alters
the splicing of transcripts for genes involved in RNA processing and maturation. Finally,
depletion of SRSF2 enhances reovirus replication and cytopathic effect, suggesting that
T1L 2 modulation of splicing benefits the virus. We provide here the first report of viral
antagonism of the splicing factor SRSF2 and suggest that the consequences to the cell
are global.
RESULTS
2 undergoes constant nuclear shuttling, but the predominant intracellular
localization is strain specific. Reovirus replication is exclusively cytoplasmic (4), and
yet the reovirus protein 2 can translocate to the nucleus (10, 11, 14). Given that the
capacity for reovirus 2 to repress IFN- signaling is virus strain specific (6, 7), we
probed 2 intracellular localization further. Notably, we found that the predominant
intracellular localization of 2 is also strain specific. T1L-2-HA localized primarily to the
nucleus, whereas T3D-2-HA localized to the cytoplasm (Fig. 1A). Interestingly, nuclear
T1L 2 localized to intranuclear filamentous structures reminiscent of microtubules and
also to discrete aggregates (Fig. 1A and B). T1L 2 nuclear localization is dependent on
the nuclear export signal receptor protein CRM1/exportin 1 (10). To determine whether
FIG 1 2 undergoes constant CRM1-dependent nuclear shuttling, but the predominant intracellular localization is strain
specific. (A) AD-293 cells were transfected with reovirus T1L- or T3D-M1-HA for 20 h and treated with medium alone (mock)
or the CRM1 inhibitor LMB for 5 h. Arrows depict 2 localization to intranuclear bodies. Scale bar, 20 m. (B) The percentage
of cells in panel A displaying the indicated nuclear bodies is presented for four independent experiments (means  the SEM;
n  6 to 61 cells per condition). (C) The percentage of cells in panel A displaying nuclear 2 is presented for two to four
independent experiments (means  the SEM; n  46 to 197 cells per condition). (D) AD-293 cells were cotransfected with
reovirus T1L- or T3D-M1-HA and either an eGFP or eGFP-CRM1 plasmid. Scale bar, 10 m. (E) The percentage of cotransfected
cells in panel D displaying nuclear 2 is presented for two independent experiments (means  the SEM; n  18 to 71 cells
per condition). *, Significantly different (P  0.05).
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T3D 2 has the ability to transiently shuttle to the nucleus and associate with similar
subnuclear structures, we inhibited CRM1 with the irreversible inhibitor leptomycin B
(LMB) (16) for 5 h prior to immunostaining (Fig. 1A and C). Treatment with LMB revealed
that T3D 2 does indeed shuttle into the nucleus, but the predominant localization is
cytoplasmic under normal nuclear protein export conditions. To further probe nuclear-
cytoplasmic shuttling, eGFP-CRM1 or an eGFP empty vector control was coexpressed
with 2 (Fig. 1D and E). As expected, T1L 2 was found mainly in the nucleus when
coexpressed with eGFP but was found in the cytoplasm in cells overexpressing CRM1.
Together, the results indicate that 2 undergoes constitutive CRM1-dependent
nuclear-cytoplasmic shuttling, but the predominant localization is reovirus strain spe-
cific. Interestingly, even when T3D 2 accumulated at high levels in the nucleus upon
CRM1 inhibition (Fig. 1A), it never associated with subnuclear structures, as seen for T1L
2. T1L 2 is known to bind and stabilize microtubules in the cytoplasm (11), but
association with subnuclear aggregates has not been previously described. Although
the role of intranuclear bodies in the life cycle of several viruses is of increasing interest
(17), a role for 2 in the nucleus has not been previously identified.
Intranuclear 2 localizes to nuclear speckles. To determine the nature of the
intranuclear T1L 2 structures, AD-293 cells were transfected with 2-HA and immu-
nostained for markers of candidate nuclear bodies. Although viruses are known to
modulate promyelocytic leukemia (PML) body function, particularly relating to the IFN
system (reviewed in references 18 and 19), T1L 2 did not colocalize with PML bodies
(Fig. 2A). Similarly, 2 did not colocalize with coilin (Fig. 2B), a marker of Cajal bodies
(20). T1L 2, however, colocalized with the serine/arginine-rich splicing factor 2 (SRSF2;
previously known as SC35 [15]), a marker of nuclear speckles (Fig. 2C). In metazoans,
nuclear speckles are enriched in mature snRNPs, non-snRNP pre-mRNA splicing factors,
and polyadenylated RNA (21–23). Association of 2 with nuclear speckles was specific
to T1L 2, since T3D 2 failed to associate with SRSF2 even after treatment with LMB
to induce its nuclear localization (Fig. 2D).
Amino acid 208 in 2 determines 2 localization to nuclear speckles during
infection. Amino acid 208 in the 2 protein determines several strain-specific differ-
ences in 2 function (7, 11, 12). To determine whether this amino acid is also a
determinant of 2 localization to nuclear speckles, AD-293 cells were infected with
either the parental reovirus strains T1L or T3D or recombinant mutant viruses and then
immunostained (Fig. 3). As expected (11), 2 localized to cytoplasmic viral factories that
displayed either a filamentous or globular morphology during T1L or T3D infection,
respectively. In addition, T1L but not T3D 2 colocalized with SRSF2 in nuclear speckles
(in 61.5%  3.3% versus 0.0% of infected cells, respectively), a finding consistent with
our results using plasmid-derived 2 (Fig. 2). Remarkably, substitution of T3D 2 amino
acid 208 with that of T1L (T3D-S208P) induced 2 localization to nuclear speckles (in
50.9%  2.7% of infected cells), whereas this localization was lost in a T3D virus
expressing T1L 2 with amino acid 208 reverted to that of T3D (T3D T1L-M1 P208S;
0.0% of infected cells). Together, results demonstrate that strain-specific differences in
2 amino acid 208 are both required and sufficient for 2 localization to nuclear
speckles during reovirus infection.
2 alters the localization of SRSF2 in a microtubule-dependent manner. Inter-
estingly, ectopic expression of T1L 2 resulted in the mislocalization of SRSF2 to
filamentous structures in approximately half of transfected L929 or AD293 cells (Fig. 4A,
E, and F). This effect was specific for SRSF2, since T1L 2 did not affect localization of
the nuclear speckle matrix protein Son (Fig. 4B). T1L 2 binds to and stabilizes
cytoplasmic microtubules (11) and, not unexpectedly, T1L 2 colocalized with nuclear
alpha-tubulin in nuclear filaments (Fig. 4C). To determine whether T1L 2-induced
changes in SRSF2 localization were a consequence of 2 association with nuclear
microtubules, cells were treated with nocodazole and paclitaxel to inhibit polymeriza-
tion of or to stabilize microtubules, respectively (24), and the cytoskeletal effects of
these drugs were confirmed (Fig. 4D). Depolymerization of microtubules with nocoda-
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FIG 2 Intranuclear T1L 2 specifically localizes to nuclear speckles. AD-293 cells were transfected with reovirus T1L- or T3D-M1-HA for
20 h, fixed, and immunostained with antibodies against HA and markers of PML bodies (PML) (A), Cajal bodies (coilin) (B), or nuclear
speckles (SRSF2) (C). (D) AD-293 cells were transfected with T3D M1-HA for 18 h, treated with LMB for 5 h, and immunostained as in
panel C. Nuclei were counterstained with DAPI. Histograms display measured fluorescence intensity along the drawn line in the
overlay inset panels. Scale bar, 10 m.
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zole reduced the fraction of T1L 2-expressing cells that displayed mislocalized SRSF2,
demonstrating that this TL 2 effect requires microtubules (Fig. 4E and F). However,
stabilization of microtubules with paclitaxel did not alter SRSF2 localization in T3D
2-expressing cells demonstrating that stabilized microtubules are not sufficient to
support 2 effects on SRSF2 localization (Fig. 4E and F). Together, results demonstrate
that T1L 2, but not T3D 2, alters the localization of SRSF2 to filamentous nuclear
structures, likely by interactions with both microtubules and SRSF2.
2 forms a complex with the pre-mRNA splicing factor SRSF2. To determine
whether T1L 2 interacts with SRSF2, we first expressed T1L- and T3D-2-HA in AD-293
cells and performed an in situ proximity ligation assay (PLA [25]) (Fig. 5A). Antibody
against tubulin was used as a control for the approach and, as expected, T1L 2-HA
generated much greater PLA signals than T3D 2-HA did (Kruskal-Wallis nonparametric
test; P  0.001). Importantly, T1L 2-HA also generated much greater PLA signals than
T3D 2-HA did with endogenous SRSF2 in the nucleus (Kruskal-Wallis nonparametric
test; P  0.001). Consistent with the lack of 2-mediated changes in Son localization
(Fig. 4B), PLA experiments demonstrated that T1L 2-HA does not interact with Son
(data not shown). Next, we confirmed formation of a complex between 2 and SRSF2
biochemically by coimmunoprecipitation of cell lysates. AD-293 cells were cotrans-
FIG 3 A single amino acid in 2 determines 2 localization to nuclear speckles during reovirus infection. AD-293
cells were infected with the indicated viruses for 20 h, fixed, and immunostained for 2 and SRSF2. Nuclei were
counterstained with DAPI. Histograms display measured fluorescence intensity along the drawn line in the overlay
inset panels. The results are representative of at least two independent experiments. Scale bar, 10 m.
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fected with T1L-M1-HA and myc-tagged SRSF2 (because endogenous SRSF2 is not
expressed at sufficient levels) or myc-tagged IRF9 as a negative control (Fig. 5B).
Myc-tagged SRSF2, but not myc-tagged IRF9, coimmunoprecipitated with T1L 2-HA.
Together, results demonstrate that T1L-2 but not T3D-2 forms a complex with both
microtubules and SRSF2 in the nucleus.
2 nuclear localization requires SRSF2 expression. Given the impact of T1L 2
on SRSF2 localization, we next sought to determine whether SRSF2 affects 2 local-
ization. SRSF2 was depleted by small interfering RNA (siRNA) in L929 cells (Fig. 6A), T1L-
or T3D-M1-HA were transfected, and 2 localization was assessed by immunofluores-
cence (Fig. 6B). As expected, in control siRNA-transfected cells, T1L 2 and T3D 2
localized primarily to the nucleus and the cytoplasm, respectively. However, T1L 2
localization became primarily cytoplasmic in cells with reduced SRSF2 expression,
mimicking T3D 2. Thus, SRSF2 function is required for T1L 2 nuclear localization
where, given the exclusively nuclear location of SRSF2 (26), 2 likely subsequently
forms a complex with SRSF2.
FIG 4 T1L 2 alters the localization of SRSF2 by a microtubule-dependent mechanism. (A) L929 and AD-293 cells were transfected
with T1L M1-HA for 20 h, fixed, and immunostained using antibodies against HA and SRSF2. Nuclei were counterstained with DAPI.
(B) AD-293 cells were transfected as in panel A and immunostained using antibodies against HA and Son. (C) Three-dimensional
reconstruction of z-stacks were generated from T1L M1-HA-transfected AD-293 cells immunostained with antibodies against HA
and alpha-tubulin. (D) AD-293 cells were treated with either media alone (Mock), 10 M nocodazole, or 10 M paclitaxel for 6 h.
The morphology of microtubules was visualized by immunostaining against -tubulin. (E) AD-293 cells were transfected with T1L
M1-HA for 20 h and treated with either media alone (Mock), 10 M nocodazole, or 10 M paclitaxel for 6 h. The cells were
immunostained as in panel A. (F) Quantitation of panel E. Results are means  the SEM (n  141 to 489 cells per condition) and
are representative of at least two independent experiments. All scale bars, 10 m.
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Depletion of SRSF2 increases reovirus replication and cytopathic effect and
impact is strain specific. The interaction of T1L 2 with SRSF2 suggested the possi-
bility that reovirus modulates SRSF2 function to generate a more favorable cell envi-
ronment. To determine whether SRSF2 affects viral replication and cytopathic effect,
FIG 5 T1L 2 forms a complex with SRSF2 in the nucleus. (A) AD-293 cells were transfected with T1L M1-HA for 20 h, fixed, and subjected
to a proximity ligation assay (PLA) using the indicated primary antibodies. Cells were imaged by confocal microscopy to obtain z-stack
images of PLA signals (red) and nuclei (blue) representative of the total volume of the cell in the z axis. Scale bar, 10 m. Quantitation
of PLA results expressed as number of PLA dots per cell (n 66 to 82 cells per condition) for a representative of at least three independent
experiments. *, Significantly different from T3D 2-HA (P  0.001). (B) AD-293 cells were transfected with the indicated plasmids,
whole-cell lysates were immunoprecipitated using anti-HA-conjugated agarose beads, and lysates (input) and immunoprecipitated
extracts (IP) were resolved by SDS-PAGE for immunoblotting. The results are representative of at least two independent experiments. It
is unclear why overexpressed SRSF2 appears as two distinct bands, but the upper band corresponds to SRSF2 migration in specifications
provided with the antibody.
FIG 6 SRSF2 is required for 2 nuclear localization. L929 cells were transfected with the indicated siRNA for 72 h and
transfected with the indicated expression plasmids for 18 h. (A) Cells were lysed, and protein fractions were resolved by
SDS-PAGE for transfer and immunoblotting with the indicated antibodies. SRSF1 (negative control) or SRSF2 band
intensities are expressed relative to control siRNA-transfected cells. (B) The cells were fixed and immunostained using
antibodies against HA and SRSF2. Nuclei were counterstained with DAPI. Quantitated results (n  13 to 51 cells per
condition) are representative of two independent experiments. Scale bar, 20 m.
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L929 cells were depleted of SRSF2 and then infected with T1L or T3D. SRSF2 depletion
increased T1L but not T3D replication and cytopathic effect in both primary (Fig. 7A and
B) and secondary infections (Fig. 7C and D). The absence of an effect of SRSF2 depletion
on T3D infection suggests that SRSF2-independent events are the predominant deter-
minants of T3D replication in L929 cells. The increased T1L replication and cytopathic
effect suggest that T1L 2 does not inhibit SRSF2 activity entirely and that further
depletion of SRSF2 is beneficial to the virus.
Reovirus T1L alters cellular mRNA splicing. SRSF2 is a pre-mRNA splicing factor,
but reovirus replication is exclusively cytoplasmic, and there is no evidence that any
reovirus RNAs are spliced (4). We therefore used RNA-seq to determined whether
reovirus T1L but not T3D alters cellular mRNA splicing. Because T3D induces signifi-
cantly more IFN- than T1L does (6, 7, 27) and because IFN- alone alters mRNA
splicing of some IFN-stimulated genes (28), we compared mock-infected, untreated
cells to mock-infected or reovirus-infected cells stimulated with IFN-. This identifies
differences in T1L and T3D effects on splicing separate from differences in their
induction of IFN- and subsequent IFN- effects on splicing. The results from RNA
sequencing (RNA-seq) were analyzed by the mixture-of-isoforms (MISO) statistical
model (29) to assess changes in mRNA alternative splicing (Fig. 8A; see also Tables S1
to S3 in the supplemental material). IFN- stimulation generated 42 novel splicing
variants in 41 different genes relative to untreated cells. Excluding those IFN--induced
variants, T3D infection generated 142 novel splicing variants while, remarkably, T1L
generated 369. Only 35 of these variants were found to overlap between the two
reovirus strains, resulting in a total of 334 and 107 unique splicing events induced in
297 and 97 genes by T1L and T3D, respectively. Splicing events that were induced only
in T1L were confirmed by quantitative reverse transcription-PCR (qRT-PCR) for two
cases (RanBP3 and SRSF3) identified by MISO analysis (Fig. 8B). Whereas T3D also
altered RanBP3 and SRSF3 splicing to some extent (2.4- and 2.5-fold, relative to the
Mock group), T1L altered their splicing much more dramatically (10.4- and 10.8-fold,
respectively). Moreover, these qRT-PCR results confirmed that IFN- has minimal or no
impact on viral effects on splicing and that the same 2 amino acid that determines 2
association with SRSF2 (Fig. 3) determines reovirus effects on splicing (S208P altered
RanBP3 and SRSF3 splicing 7.0- and 11.5-fold, respectively, Fig. 8B). Thus, while both
reovirus strains induce unique splicing variants, T1L induces more than three times
more than T3D does (RNA-seq results: chi square, P  0.001), and a single 2 amino
acid can determine reovirus effects on splicing.
To gain further insights into reovirus-induced global changes in host mRNA splicing,
we used Ingenuity pathway analysis (IPA) and gene ontology (GO) analysis. Specifically,
we performed IPA on the 297 and 97 genes whose splicing was altered uniquely by T1L
FIG 7 SRSF2 effects on reovirus replication and cytopathic effect are strain-specific. (A) L929 cells were transfected with the indicated siRNA for
72 h and infected with reovirus at an MOI of 5 PFU per cell. The viral titer was determined by plaque assay at 24 or 48 h postinfection (single
cycle infection). The results are means of four replicate samples  the standard deviations (SD). (B) L929 cells were transfected as in panel A and
infected with the indicated virus at an MOI of 100 PFU per cell. Cell viability was measured using an MTT assay at 24 h postinfection. The results
correspond to four replicate wells per infection and are expressed as means  the SD relative to mock-infected cultures for the corresponding
siRNA. (C) Same as for panel A, but the cells were infected at an MOI of 0.1 and harvested at 5 days postinfection. (D) Same as for panel B, but
the cells were infected at an MOI of 0.1 and assessed at 5 days postinfection (multiple cycle infection). All results in all panels are representative
of at least two independent experiments. *, Significantly different from the “control siRNA  T1L infected” group (P  0.05).
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or by T3D, respectively. The pathways most affected by T1L involved RNA posttran-
scriptional modifications (Fig. 8C). Indeed, T1L (but not T3D) altered the spicing of
SRSF3, SRSF6, SRSF7, and SRSF11 (see Table S3 in the supplemental material), all of
which have specialized roles in posttranscriptional regulation (30). Moreover, the top
five predicted upstream regulators for altered splicing events induced by T1L (but not
T3D) included SRSF1 (data not shown), another SR family member (31). Importantly, the
minimal changes in splicing that occurred during T3D did not cluster in any of these
categories, and there was no overlap with those obtained for T1L. Lastly, we used the
network of genes affected by T1L with the highest statistical significance to create a
web of known and predicted interactions. One-third of the genes in the network related
to mRNA splicing or mRNA processing (data not shown). These IPA results were
supported by GO analysis of the same data sets. Specifically, the top two processes for
T1L were “mRNA processing” and “ribonucleoprotein complex assembly,” whereas
those were 47th and 8th in priority for T3D, respectively (T1L different from T3D at P 
0.001 and P  0.05, respectively).
FIG 8 Reovirus infection alters cellular mRNA splicing. (A) Venn diagram indicating differences in splicing based on MISO analysis of RNA-seq
results. (B) Confirmation of differential expression of novel splicing variants using qRT-PCR. L929 cells were infected and stimulated with IFN-
using conditions identical to those used for RNA-seq. Transcripts with a specific exon skipped or spliced-in (as identified by RNA-seq) were
quantitated by qRT-PCR for two representative genes. The results are expressed as a ratio of the two splicing events to capture the events
comprising MISO analysis. The results of statistical analyses (P  0.05), indicated by lowercase letters, were as follows: a, mock different from T1L
and S208P; b, mock or mockIFN different from all viruses or virusesIFN; c, T1L or T1LIFN different from T3D or T3DIFN; d, T3D or T3DIFN
different from S208P or S208PIFN; and e, S208P or S208PIFN not different from T1L or T1LIFN. (C) IPA results for genes whose splicing was
altered uniquely by either T1L (297 genes) or T3D (97 genes) and IFN- stimulation, excluding genes whose splicing was altered by IFN-
stimulation alone.
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In sum, results suggest that SRSF2 is required for T1L 2 nuclear localization
whereupon T1L 2 forms a complex with SRSF2 and antagonizes the organization of
nuclear speckles, resulting in dysregulated splicing of other splicing factors and regu-
lators of mRNA at the posttranscriptional level to benefit viral replication (Fig. 9).
DISCUSSION
To replicate efficiently, viruses must create favorable cell conditions and overcome
cell antiviral responses. Here, we report that the 2 protein from strain T1L localizes to
nuclear speckles, where it forms a complex with and alters the localization of the
pre-mRNA splicing factor SRSF2. Moreover, infection with reovirus T1L alters mRNA
splicing of genes involved in mRNA processing and maturation, likely as a consequence
of T1L 2 antagonistic effects on SRSF2. Finally, depletion of SRSF2 enhances reovirus
replication and cytopathic effect, suggesting that T1L 2 modulation of splicing
benefits the virus. This provides the first report of viral antagonism of the splicing factor
SRSF2 and suggests that by altering mRNA processing and maturation, the virus
induces cell consequences that are global rather than in a single pathway.
Reovirus 2 stability, repression of IFN- signaling, and stabilization of microtubules
are all determined by a single amino acid polymorphism in the 2 protein (6, 7, 11).
Here, we demonstrate that this amino acid similarly determines 2 localization to
nuclear speckles (Fig. 3). The common dependence on a single amino acid could reflect
its impact on 2 stability or its impact on function. The N terminus of 2 includes a
polybasic region that can function as a nuclear localization signal (10) and, interestingly,
domains that are rich in basic amino acids have been identified as nuclear speckle-
targeting signals (32). However, this 2 polybasic region is conserved between T1L and
T3D strains, indicating that the primary protein sequence alone does not predict its
localization and that other factors contribute to the differential localization of 2. This
complexity in determinants of 2 localization to intracellular compartments is high-
lighted by the observation that SRSF2 is required for 2 nuclear localization (Fig. 6) and
that T3D 2 does not associate with nuclear speckles even when concentrated in the
nucleus after inhibition of nuclear export (Fig. 2D). The requirement for SRSF2 could
reflect trapping of 2 in a complex, an impact on nuclear import or export processes,
or an impact on cell proteins that affect 2 itself (Fig. 9). Posttranslational modifications
of 2, including acetylation (33) and phosphorylation (34), have been reported, and yet
the impact(s) of these modifications on 2 function has not been fully elucidated.
Future studies will address the roles of SRSF2 and posttranslational modifications on 2
subcellular localization.
FIG 9 Model for T1L 2 interactions with SRSF2 and impact on cell RNA splicing. Upon viral infection (diagram 1), cell splicing
protein SRSF2 modulates T1L 2 (possibly through effects on posttranslational modification enzymes) or nuclear protein
transport effectors, resulting in translocation of T1L 2 to the nucleus. Once in the nucleus (diagram 2), T1L 2 forms a
complex with SRSF2 and alters it function to modulate the cell response.
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Multiple viruses regulate the cell splicing machinery to generate alternative viral
RNA products. Several RNA viruses (35–38) and DNA viruses (39) use extensive alter-
native splicing of their mRNAs. The influenza A virus NS1 protein disorganizes nuclear
speckles and Cajal bodies and binds members of the snRNP family of splicing factors
and proteins required for 3=-terminal polyadenylation of host transcripts to facilitate
splicing of viral RNAs (35). Retroviruses regulate cell splicing machinery to balance
generation of viral mRNAs with maintenance of unspliced RNA for production of viral
progeny (40, 41). There is no evidence for splicing of viral RNA for the cytoplasmically
replicating reovirus (4). Reovirus RNAs also lack modifications at their 3= termini (4);
another RNA modification function associated with nuclear speckles (42–44). Finally, we
did not detect any redistribution of splicing factors to cytoplasmic VFs during reovirus
infection (data not shown). Thus, there is no evidence that reovirus modulation of
SRSF2 affects viral RNAs. Instead, reovirus likely modulates the cell transcriptome to its
benefit.
Alternative splicing of cell mRNAs can affect cell function and disease (45–47), and
several viruses modulate cell splicing machinery to alter the cell transcriptome. The
adenovirus E4-ORF4 antagonizes the function of SRSF1 and SRSF9 by promoting their
dephosphorylation (48, 49). The herpes simplex virus ICP27 protein binds the SR protein
kinase 1 (SRPK1), resulting in its relocalization from the cytoplasm to the nucleus to
dephosphorylate SR proteins and regulate host mRNA splicing events (50–52). The
vaccinia virus VH1 phosphatase appears to directly dephosphorylate SR proteins (53).
Epstein-Barr virus (EBV) itself encodes a splicing factor, SM, that influences splicing and
processing of host pre-mRNAs (54, 55). Splice variants, including those that encode
dominant negative proteins, have been described for several genes involved in the
IFN-/ response (56–63). Notably, the EBV SM protein skews the mRNA splicing
patterns of STAT1, enhancing production of the dominant-negative STAT1 isoform
(55). Very recently, it has been shown that the NS5 protein of dengue virus binds to and
interferes with components of the U5 snRNP particle and alters mRNA splicing of
several antiviral factors (64). In contrast to our results for reovirus, dengue NS5 does not
appear to affect the intranuclear localization of its splicing targets (64). Finally, in a
recent report reovirus T3D was shown to alter cell mRNA splicing, but the impact on
viral replication and the underlying mechanism were not investigated (65). It is inter-
esting that a single reovirus protein, 2, can modulate both IFN signaling (7) and SRSF2
function to benefit the virus. The results suggest that this protein has evolved to target
both a specific antiviral pathway and mRNA maturation for more global effects.
Several SR proteins play roles in addition to those in splicing that affect mature
mRNA expression and nuclear export (30). For example, SRSF1 participates in the
organization of nuclear speckles and in the promotion of decay of aberrantly spliced
transcripts (31, 66, 67), whereas SRSF2 influences transcriptional elongation of some
mRNAs (68). With the exception of SRSF2, mammalian SR proteins constitutively shuttle
between the nucleus and cytoplasm (26). Once in the cytoplasm, SRSF1 impacts
translation by modulating mRNA entrance into polyribosomes (69, 70). Lastly and
perhaps most intriguingly, SRSF1 has been associated with RIG-I and RNA polymerase
III-dependent sensing of transfected non-self cytosolic DNA to facilitate IFN- produc-
tion (71); however, its role during viral infection remains unclear. Similarly, the spliceo-
somal protein SNRNP200 can also translocate to the cytoplasm, where it modulates the
viral induction of IFN- (72). Although T1L did not affect splicing of SRSF1 or SNRNP200
mRNA, the loss of SRSF2 can affect SRSF1 function (73), and the regulation of snRNPs
is complex, leaving open the possibility that T1L alters the cytoplasmic function of
spliceosomal proteins to benefit the virus.
T1L infection alters SRSF3 splicing (see Table S3 in the supplemental material),
suggesting another possible mechanism by which T1L 2 interactions with SRSF2 could
impact cell RNA function. SRSF3 (previously known as SRp20 [15]) is involved in 5=
cap-independent internal ribosome entry site (IRES)-mediated translation of picornavi-
rus transcripts (74, 75). The 2A proteinase of several picornaviruses induce a change in
localization of SRSF3 from the nucleus to the cytoplasm and stress granules (76), and
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depletion of SRSF3 impacts the efficiency of IRES-mediated translation (74). Reovirus
transcripts are 5= capped and undergo 5=-cap-dependent translation in ribosomes
within membrane-associated VFs (4, 5, 77). Thus, it is unlikely that reovirus modulation
of SRSF3 splicing is related to IRES-dependent translation. However, T1L infection
induces novel splice variants of SRSF3, SRSF6, SRSF7, and SRSF11 (see Table S3 in the
supplemental material), all of which have specialized roles in posttranscriptional reg-
ulation (30). Thus, reovirus modulation of the cell response may be indirectly mediated
through a dysregulation of mRNA nuclear export, processing, nonsense-mediated
decay, and/or efficient translation through the targeting of SRSF2 and changes in the
isoforms of other SR proteins.
Lastly, reovirus 2 repression of the IFN- response is a determinant of reovirus
induction of myocarditis (7, 27), and the same 2 amino acid polymorphism that
determines this repression and severity of myocarditis (7) determines 2 association
with SRSF2 (Fig. 3). Together, these results suggest that SRSF2 could participate in
protecting the heart against viral myocarditis. While this could reflect SRSF2 effects on
the IFN response, it has been shown that mutations and/or decreased expression of
splicing factors results in cardiac development defects (45), and cardiac tissue-specific
ablation of SRSF2 results in dilated cardiomyopathy (78). The fact that viruses, such as
adenoviruses, herpesviruses, and reoviruses, known to induce myocarditis (79) can
modulate splicing factors raises the intriguing possibility that altered splicing repre-
sents yet another mechanism by which viruses induce cardiac damage.
MATERIALS AND METHODS
Cells. Mouse L929 cells were maintained in minimal essential medium (MEM; SAFC Biosciences) as a
suspension culture supplemented to contain 5% fetal calf serum and 2 mM L-glutamine. AD-293 cells
were maintained in high glucose Dulbecco MEM (DMEM; Gibco) supplemented to contain 10% fetal calf
serum and 1% of sodium pyruvate. Exponentially growing L cells or trypsinized AD-293 cells were plated
and incubated for at least 3 h prior to transfection or infection.
Viruses. All viruses were CsCl-purified, low-passage-number stocks originating from plaques of either
cultured virus or virus generated by reverse genetics (80) as previously described (6, 7). The results were
the same regardless of virus source.
Plasmids and plasmid transfections. A plasmid expressing C-terminus hemagglutinin (HA)-tagged
T1L 2 in a pCAGGs backbone was described previously (34). The C-terminus HA-tagged T3D 2 was
generated from pCAGGs-M1-T3D (6) using a similar strategy and the primer 5=-CCCGGGTCAGCTAGCGT
AATCTGGAACATCGTATGGGTACGCCAAGTCAGATCGGAAAGCTAGTC-3=. The eGFP-N1 and eGFP-HsCRM1
plasmids were obtained from Clontech Laboratories (catalog no. 6085-1) and GeneCopoeia (catalog no.
EX-T0446-M29), respectively. The Myc-DDK-IRF9 plasmid was custom-cloned by OriGene Technologies,
Inc., using the murine IRF9 cDNA (NM_001159417) in a pCMV6 expression vector. The HsSRSF2-c-Myc in
a pcDNA3.1 backbone plasmid (81) was a gift from Kathleen Scotto (Addgene; plasmid 44721). Plasmids
were transfected using Lipofectamine 3000 (Thermo Fisher Scientific) for 20 to 24 h.
siRNAs and siRNA transfections. L929 cells were transfected for a final 60 nM concentration of
control nontargeting siRNA or siRNA against murine SRSF2 (GE Dharmacon; catalog no. D-001810-10 or
L-044306) using the transfection reagent RNAiMAX (Thermo Fisher Scientific). At 24 h posttransfection,
overlaying medium was replaced with fresh medium.
Antibodies and chemical treatments. The following antibodies and dilutions were used for
immunoblotting: anti-2 (generated against two 2 peptides by Open Biosystems; 1:1,000), anti--actin
(Santa Cruz Biotech, sc-1615-hrp; 1:3,000), anti-SRSF2 (Millipore, 04-1550; 1:1,000), anti-SRSF1 (Abcam,
ab129108; 1:350), anti-c-Myc (catalog no. sc-40, 1:3,000; Santa Cruz Biotech), goat horseradish peroxidase
(HRP)-conjugated anti-rabbit immunoglobulin (Ig; Millipore, 12-348; 1:2,000), and goat HRP-conjugated
anti-mouse Ig (Millipore, 12-349; 1:2,000). For immunoprecipitation experiments, secondary antibodies
were either TrueBlot anti-rabbit IgG-HRP or TrueBlot Ultra anti-mouse Ig-HRP (Rockland Immunochemi-
cals, 18-8816-33 and 18-8817-33; 1:1,000). Primary antibodies used for immunofluorescence and PLA
were anti-coilin (Cell Signaling Technology, 14168; 1:800), anti-SRSF2/SC35 (Abcam, ab11826; 1:1,000),
anti-Son (Abcam, ab109472; 1:200), anti-HA epitope tag (GeneTex, 18181; 1:1200; or Sigma, H6908;
1:1,000 or 1:1,200 for PLA), rabbit anti-2 antisera (82) (1:1,000), and a mix of anti-reovirus T1L and
anti-reovirus 8B mouse antisera (B. Sherry, unpublished; 1:5,000 each). The secondary antibodies were
Alexa Fluor 488- or Alexa Fluor 594-conjugated goat anti-mouse or anti-rabbit IgG (Thermo Fisher
Scientific; 1:1,000). The CRM1-inhibitor leptomycin B (LMB; Sigma, L2913) was used at a final concentra-
tion of 20 nM in supplemented DMEM. Nocodazole (Sigma, M1404) and paclitaxel (Sigma, T7191) in
dimethyl sulfoxide were used at a final concentration of 10 M in supplemented DMEM. Recombinant
mouse interferon- (PBL Assay Science, catalog no. 12410-1) was used at 1,000 U/ml diluted in
supplemented MEM.
SDS-PAGE and immunoblotting. Whole-cell protein extracts were obtained 2 days postplating
using radioimmunoprecipitation assay (RIPA) lysis buffer (50 mM Tris HCl [pH 7.4], 1% NP-40, 0.25%
sodium deoxycholate, 150 mM NaCl, 1 mM EDTA) supplemented to contain 1% sodium dodecyl sulfate
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(SDS), a cocktail of protease and phosphatase inhibitors (Sigma, catalog nos. P8340 and P2850), and 1
mM phenylmethylsulfonyl fluoride (Sigma, P7626). Protein lysates were resolved by SDS-PAGE and
transferred to a nitrocellulose membrane (GE Healthcare). Membranes were probed with the indicated
antibodies, developed using Amersham enhanced chemiluminescence (ECL) or ECL Prime kits, exposed
to film, and scanned using an HP Scanjet G4050. Band intensities were determined using the LI-COR
Biosciences Image Studio Lite Software (v5.x).
Coimmunoprecipitation. At 24 h posttransfection, AD-293 cells were harvested and lysed using a
modified RIPA buffer (10 mM Tris [pH 7.5], 150 mM NaCl, 0.5% sodium deoxycholate, 1% Triton X-100)
supplemented with 20 mM N-ethylmaleimide (Sigma, catalog no. E3786) and a cocktail of protease and
phosphatase inhibitors as described above. Lysate supernatants were incubated with EZview Red anti-HA
affinity gel (Sigma, E6779). Washed beads were boiled in Laemmli sample buffer. Supernatant was
subjected to SDS-PAGE and immunoblotting as described above.
Indirect immunofluorescence. Cells in poly-D-Lysine-coated chamber slides (BD Biosciences) were
fixed in 4% paraformaldehyde (Electron Microscopy Sciences) in phosphate-buffered saline and perme-
abilized with 0.25% Triton X-100 (Sigma). Slides were blocked with normal goat serum (Sigma, catalog
no. G9023), incubated in DAPI (4=,6-diamidino-2-phenylindole; Sigma, D8417), immunostained with the
indicated primary and secondary antibodies, and preserved with ProLong Gold (Invitrogen). For immu-
nostaining of 2 and SRSF2 during reovirus infection, the cells were fixed in 100% methanol.
In situ proximity ligation assay. Transfected cells in poly-D-lysine-coated chamber slides were fixed
with 4% paraformaldehyde, permeabilized in 0.25% Triton X-100, blocked with Duolink blocking solution,
incubated with primary antibodies, and then probed using a Duolink PLA kit (Sigma, catalog no.
DUO92101). Dried slides were mounted on Duolink mounting medium with DAPI and imaged as z-stacks
by confocal microscopy.
Quantitative (real-time) reverse transcription-PCR. For confirmation of the MISO results, oligo-
nucleotide primers were designed to amplify transcripts that either skipped or spliced-in a specific exon,
as identified by RNA-seq. The primers were as follows: RanBP3 skipped exon (forward, 5=-CCGTCTGTCT
TTGTGTTTCAA-3=; reverse, 5=-GCTGCTCTTCTCTTCTGAGTGA-3=), RanBP3 spliced-in exon (forward, 5=-
CGACCGTCTGTCTTTGTGTTT-3=; reverse, 5=-AAACATGACCCCATCAAAA-3=), SRSF3 skipped exon (forward,
5=-TGATTACCGCAGGAGGAGTC-3=; reverse, 5=-GATCGAGACGGCTTGTGATT-3=), and SRSF3 spliced-in exon
(forward, 5=-TGATTACCGCAGGAGGAGTC-3=; reverse, 5=-TGACGCTGAAAGGGCTAGTT-3=). The total RNA
was harvested using an RNeasy kit (Qiagen, Inc.), treated with RNase-free DNase I (Qiagen, Inc.),
converted to cDNA by reverse transcription, and used for real-time PCR on a LightCycler 480 fluorescence
thermocyler (Roche Life Science). The reaction mixtures contained 1 Quantitech SYBR green master mix
(Qiagen) and 0.3 M (each) forward and reverse primers as previously described (83). The relative mRNA
abundance of RanBP3 and SRSF3 were normalized to GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase) by the ΔΔCp method, and the fold induction was calculated relative to mock-treated cells for each
primer pair.
Viral replication and cytopathic effect in siRNA-transfected cells. L929 cells were transfected with
siRNA as described above and infected 2 days later at the indicated multiplicity of infection (MOI). The
siRNA-mediated depletion of SRSF2 was maintained throughout the experiment (data not shown). Viral
replication and cytopathic effect were assessed by plaque assay (84) and MTT assay (27).
Confocal microscopy and image analysis. A Zeiss LSM 710 confocal microscope equipped with a
40 C-Apochromat/1.1 NA water immersion objective from the Cellular and Molecular Facility at NC
State University was used for all experiments. The pinhole diameter was maintained at 1 Airy unit, and
all images were obtained using multitrack sequential scanning for each fluorophore to prevent bleed-
through. The excitation/emission wavelengths during micrograph acquisition were as follows: 488
nm/492 to 554 nm for Alexa Fluor 488, 561 nm/584 to 666 nm for Alexa Fluor 594 and PLA Duolink Red,
and 405 nm/407 to 507 nm for DAPI. The images were processed for presentation using Photoshop CS4.
Intensity plot profiles were generated using ImageJ software (82). Quantification of in situ PLA signals per
cell was performed using the particle analysis tool of ImageJ.
RNA-seq. L929 cells were infected at an MOI of 100 PFU per cell, and at 20 h postinfection overlays
were replaced with supplemented media or mouse IFN- diluted in supplemented medium to 1,000
U/ml. After 5 h of incubation, the overlays were removed, and the total RNA was harvested, the
contaminating DNA was removed, and an aliquot of the RNA was converted to cDNA for qRT-PCR to
confirm T1L repression of IFN- signaling (data not shown). Total RNA samples were submitted to the
North Carolina State University Genomic Sciences Laboratory (Raleigh, NC) for Illumina RNA library
construction and sequencing. mRNA was purified using oligo(dT) beads [NEBNExt poly(A) mRNA mag-
netic isolation module (New England BioLabs, USA)], chemically fragmented, and primed with random
oligonucleotides for first-strand cDNA synthesis (NEBNext Ultra Directional RNA library prep kit [NEB] and
NEBNext Mulitplex Oligos for Illumina [NEB]). Second-strand cDNA synthesis was carried out with dUTPs
to preserve strand orientation information. Double-stranded cDNA was “A-tailed” for adaptor ligation
and selected for a final size of 250 to 400 bp, including adaptors (AMPure XP bead isolation; Beckman
Coulter, USA). Library enrichment was performed, and indexes were added during PCR amplification.
Libraries were pooled in equimolar amounts and sequenced on an Illumina NextSeq 500 DNA sequencer,
and real-time analysis was used to generate raw base call files, which were then demultiplexed by sample
into fastq files.
Annotation and clustering of changes in alternative splicing during reovirus infection. Only
those reads with a minimum of 50 bp were used, and all reads were trimmed to 50 bases (fastx_trimmer
tool [http://hannonlab.cshl.edu/fastx_toolkit/]). Reads were mapped to the mm10 mouse reference
genome using TopHat2 (85), and the results merged to create a single bam file for each sample. Picard
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Tools’ CollectInsertMetrics (http://picard.sourceforge.net) was run on each of these bam files. MISO
(mixture-of-isoforms) software (29) was run to calculate the isoform expression “percent spliced isoform”
() value. The mm1v2 known skipped exon events provided on the MISO website were included in the
run. The  values calculated for the exons for each sample were compared, and a Bayes factor was
computed. The Bayes Factor results were filtered, requiring at least one read supporting each isoform
and at least a total of 10 reads across all isoforms. In addition, the absolute difference in  values must
be 0.20 and a Bayes factor of 10. Analyses were performed by IPA (Ingenuity) and a generic gene
ontology (GO) term mapper (http://go.princeton.edu/cgi-bin/GOTermMapper).
Statistical analysis. Unless stated otherwise, a Student two-sample t test (pooled variance) was
applied (Systat software). Results were considered significant for P value of 0.05.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
JVI.02488-16.
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